Contact
    Start Publications Antibody-Enabled Antimicrobial Nanocapsules for Selective ...
    ←  Publication Finder
    QSense

    Antibody-Enabled Antimicrobial Nanocapsules for Selective Elimination of Staphylococcus aureus

    Year: 2020

    Journal: ACS Appl. Mater. Interfaces, Volume 12, AUG 12, page 35918–35927

    Authors: Ivanova, Kristina; Ivanova, Aleksandra; Ramon, Eva; Hoyo, Javier; Sanchez-Gomez, Susana; Tzanov, Tzanko

    Keywords: Staphylococcus aureus; antibiotic resistance; essential oil; zein nanocapsules; targeting antibody; selective antibacterial activity

    Targeted bactericide nanosystems hold significant promise to improve the efficacy of existing antimicrobials for treatment of severe bacterial infections, minimizing the side effects and lowering the risk of the development of antibiotic resistance. In this work, we developed antibody-functionalized nanocapsules (NCs) containing antibacterial essential oil (EO) for selective and effective eradication of Staphylococcus aureus. Antibacterial EO NCs were produced via self-assembly nanoencapsulation in the plant-derived protein zein. The obtained EO NCs were decorated with aminocellulose to provide more reactive surface groups for carboxyl-to-amine immobilization of a antibody that is specific against S. aureus. The antibody-enabled EO NCs (Ab@EO NCs) demonstrated 2-fold higher bactericidal efficacy against the targeted bacterium compared to the pristine EO NCs at the same concentrations. The improved antibacterial effect of the Ab@EO NCs toward S. aureus was also confirmed in a real-time assay by monitoring bacterial cells elimination using a quartz crystal microbalance. Furthermore, the Ab@EO NCs selectively decreased the load and changed the cell morphology of the targeted S. aureus in a mixed inoculum with nontargeted Pseudomonas aeruginosa. Applying the nanoformulated antibacterial actives to an in vitro coculture model of the bacteria and skin fibroblasts resulted in suppression of S. aureus growth while preserving the human cells viability. The novel antibody-enabled antibacterial NCs showed potential for improving the treatment efficacy of staphylococcal infections, minimally affecting the beneficial microbial and human cells.
    View publication